Personalized participatory medicine: sharing knowledge and uncertainty

被引：4
作者：
Gurwitz, David [1 ]
Lunshof, Jeantine E. [2 ,3 ,4 ,5 ]
机构：
[1] Tel Aviv Univ, Sackler Fac Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel
[2] Maastricht Univ, Fac Hlth Med & Life Sci, Maastricht, Netherlands
[3] Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Mol Cell Physiol, NL-1081 HV Amsterdam, Netherlands
[4] Netherlands Inst Syst Biol, NL-1081 HV Amsterdam, Netherlands
[5] Harvard Univ, Sch Med, Dept Genet, Ctr Excellence Genom Sci & Personal Genome Projec, Boston, MA 02115 USA
来源：
GENOME MEDICINE | 2011年 / 3卷
关键词：
Tamoxifen; Personalized Medicine; Breast Cancer Recurrence; Alternative Treatment Option; Personal Genome;
D O I：
10.1186/gm285
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Informing patients about risks and benefits of alternative treatment options and choosing between them is becoming a bigger challenge as knowledge about the relationship between the individual's genetic profile and the efficacy and safety of available medications accumulates. Putting personalized medicine into practice requires new modes of information sharing and decision making by patient and physician. This is illustrated by a case study on treatment choices of breast cancer patients following genotyping for CYP2D6, recently published in Genome Medicine.
引用
收藏
页数：2
相关论文
共 10 条
  • [1] Endoxifen, a New Cornerstone of Breast Cancer Therapy: Demonstration of Safety,Tolerability, and Systemic Bioavailability in Healthy Human Subjects
    Ahmad, A.
    Shahabuddin, S.
    Sheikh, S.
    Kale, P.
    Krishnappa, M.
    Rane, R. C.
    Ahmad, I.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (06) : 814 - 817
  • [2] Clinical assessment incorporating a personal genome
    Ashley, Euan A.
    Butte, Atul J.
    Wheeler, Matthew T.
    Chen, Rong
    Klein, Teri E.
    Dewey, Frederick E.
    Dudley, Joel T.
    Ormond, Kelly E.
    Pavlovic, Aleksandra
    Morgan, Alexander A.
    Pushkarev, Dmitry
    Neff, Norma F.
    Hudgins, Louanne
    Gong, Li
    Hodges, Laura M.
    Berlin, Dorit S.
    Thorn, Caroline F.
    Sangkuhl, Katrin
    Hebert, Joan M.
    Woon, Mark
    Sagreiya, Hersh
    Whaley, Ryan
    Knowles, Joshua W.
    Chou, Michael F.
    Thakuria, Joseph V.
    Rosenbaum, Abraham M.
    Zaranek, Alexander Wait
    Church, George M.
    Greely, Henry T.
    Quake, Stephen R.
    Altman, Russ B.
    [J]. LANCET, 2010, 375 (9725) : 1525 - 1535
  • [3] Increasing Tamoxifen Dose in Breast Cancer Patients Based on CYP2D6 Genotypes and Endoxifen Levels: Effect on Active Metabolite Isomers and the Antiestrogenic Activity Score
    Barginear, M. F.
    Jaremko, M.
    Peter, I.
    Yu, C.
    Kasai, Y.
    Kemeny, M.
    Raptis, G.
    Desnick, R. J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (04) : 605 - 611
  • [4] The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
    Goetz, Matthew P.
    Knox, Stacey K.
    Suman, Vera J.
    Rae, James M.
    Safgren, Stephanie L.
    Ames, Matthew M.
    Visscher, Daniel W.
    Reynolds, Carol
    Couch, Fergus J.
    Lingle, Wilma L.
    Weinshilboum, Richard M.
    Fritcher, Emily G. Barr
    Nibbe, Andrea M.
    Desta, Zeruesenay
    Nguyen, Anne
    Flockhart, David A.
    Perez, Edith A.
    Ingle, James N.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 101 (01) : 113 - 121
  • [5] Pharmacogenetics in the laboratory and the clinic
    Goldstein, DB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) : 553 - 556
  • [6] Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment
    Lorizio, Wendy
    Rugo, Hope
    Beattie, Mary S.
    Tchu, Simone
    Melese, Teri
    Melisko, Michelle
    Wu, Alan H. B.
    Lawrence, H. Jeffrey
    Nikoloff, Michele
    Ziv, Elad
    [J]. GENOME MEDICINE, 2011, 3
  • [7] Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
    Schroth, Werner
    Goetz, Matthew P.
    Hamann, Ute
    Fasching, Peter A.
    Schmidt, Marcus
    Winter, Stefan
    Fritz, Peter
    Simon, Wolfgang
    Suman, Vera J.
    Ames, Matthew M.
    Safgren, Stephanie L.
    Kuffel, Mary J.
    Ulmer, Hans Ulrich
    Bolaender, Julia
    Strick, Reiner
    Beckmann, Matthias W.
    Koelbl, Heinz
    Weinshilboum, Richard M.
    Ingle, James N.
    Eichelbaum, Michel
    Schwab, Matthias
    Brauch, Hiltrud
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (13): : 1429 - 1436
  • [8] Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis
    Seruga, Bostjan
    Amir, Eitan
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (03) : 609 - 617
  • [9] Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen
    Siegelmann-Danieli, Nava
    Kurnik, Daniel
    Lomnicky, Yossi
    Vesterman-Landes, Janet
    Katzir, Itzhak
    Bialik, Martin
    Loebstein, Ronen
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2011, 125 (02) : 505 - 510
  • [10] Genomic Medicine Genomics and Drug Response
    Wang, Liewei
    McLeod, Howard L.
    Weinshilboum, Richard M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (12) : 1144 - 1153
1